Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record.

Handbook of Psychooncology

Open access
Hopwood, P·1993·British Journal of Cancer

Abstract

447 ing genes. The quality of the different papers varies, and although some of them are only descriptions of findings of different genetic alterations in small series with no emphasis on the title 'Targets for Therapy', the overall impression of the book is good. Many of the papers point to the dawning potential of oncogenes and their products as targets for specific therapy, and this is exciting reading. In the first section the epidermal growth-factor receptor homologue c-erbB-2 is the subject of most papers. The first paper gives a very good overview of the involvement of this receptor in human malignant diseases, and its role in the biology of human cancer. Production of humanised mono-clonal antibodies directed against the extra cellular domain of c-erbB-2, their antiproliferative effects on cultured tumour cell lines and on tumour xenografts seem very promising for the use of this agent in treatment of cancers involving overex-pression of this receptor. Clinical trials have started on both breast and ovarian cancer patients. Other strategies where antibodies to c-erbB-2 are coupled to a variety of toxins, drugs or isotopes are also considered in the following papers. They also show the importance of the epitope the antibody recognise in order to be effective in growth inhibition. Monoclonal antibodies against the EGF receptor also seem to be clinically useful both for radio-imaging and for therapeutic applications. These antibodies seem to act as antagonists of EGF, and such antibodies are now also used in clinical trials. The last paper in this section deals with the growing family of fibroblast growth factors (FGFs) and their receptors as possible targets for therapy. More recent experiments, unfortunately not included in the book, indicate that both FGFs and pleiotrophins are likely to be important in tumour angiogenesis. Antibodies to FGF have been coupled to toxins and have shown potential anti-cancer activity toward human breast cancers growing in nude mice. Section two deals with intracellular oncogene products as targets for therapy, and particularly the ras oncoproteins. This section is in my opinion the most exciting and best written part of the book. The first paper in this section gives an excellent overview of the mechanisms whereby intracel-lular antigens reach and can be seen by the host's immune system, and sets the framework on which therapeutic strategies can be devised. It contains illustrating figures explaining MHC class I and class II pathways, preparing the reader for the …

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.1993.361

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 338

Metadata

Authors
Hopwood, P.
Venue
British Journal of Cancer
Published
1993-08-01
Volume
68
Issue
2
Pages
447-447
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2068911518
Cited by
338
References
0
Type
book review
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Handbook of Psychooncology. https://app.cochat.ai/papers/10.1038/bjc.1993.361
The paper
Hopwood, P. (1993). Handbook of Psychooncology. British Journal of Cancer. https://doi.org/10.1038/bjc.1993.361

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.